Cargando…
TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells
BACKGROUND: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219732/ https://www.ncbi.nlm.nih.gov/pubmed/22054074 http://dx.doi.org/10.1186/1476-511X-10-199 |
_version_ | 1782216887576297472 |
---|---|
author | Zhu, Chunhua Di, Dongmei Zhang, Xiaoying Luo, Guanghua Wang, Zongchun Wei, Jiang Shi, Yuanping Berggren-Söderlund, Maria Nilsson-Ehle, Peter Xu, Ning |
author_facet | Zhu, Chunhua Di, Dongmei Zhang, Xiaoying Luo, Guanghua Wang, Zongchun Wei, Jiang Shi, Yuanping Berggren-Söderlund, Maria Nilsson-Ehle, Peter Xu, Ning |
author_sort | Zhu, Chunhua |
collection | PubMed |
description | BACKGROUND: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317. MATERIALS AND METHODS: Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR. RESULTS: When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1. CONCLUSION: The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway. |
format | Online Article Text |
id | pubmed-3219732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32197322011-11-18 TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells Zhu, Chunhua Di, Dongmei Zhang, Xiaoying Luo, Guanghua Wang, Zongchun Wei, Jiang Shi, Yuanping Berggren-Söderlund, Maria Nilsson-Ehle, Peter Xu, Ning Lipids Health Dis Research BACKGROUND: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317. MATERIALS AND METHODS: Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR. RESULTS: When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1. CONCLUSION: The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway. BioMed Central 2011-11-04 /pmc/articles/PMC3219732/ /pubmed/22054074 http://dx.doi.org/10.1186/1476-511X-10-199 Text en Copyright ©2011 Zhu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Zhu, Chunhua Di, Dongmei Zhang, Xiaoying Luo, Guanghua Wang, Zongchun Wei, Jiang Shi, Yuanping Berggren-Söderlund, Maria Nilsson-Ehle, Peter Xu, Ning TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells |
title | TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells |
title_full | TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells |
title_fullStr | TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells |
title_full_unstemmed | TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells |
title_short | TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells |
title_sort | to901317 regulating apolipoprotein m expression mediates via the farnesoid x receptor pathway in caco-2 cells |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219732/ https://www.ncbi.nlm.nih.gov/pubmed/22054074 http://dx.doi.org/10.1186/1476-511X-10-199 |
work_keys_str_mv | AT zhuchunhua to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT didongmei to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT zhangxiaoying to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT luoguanghua to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT wangzongchun to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT weijiang to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT shiyuanping to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT berggrensoderlundmaria to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT nilssonehlepeter to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells AT xuning to901317regulatingapolipoproteinmexpressionmediatesviathefarnesoidxreceptorpathwayincaco2cells |